PXR-Mediated Xenobiotic Response in the Pathogenesis Hemorrhagic Shock
PXR-Mediated Xenobiotic Response in the Pathogenesis Hemorrhagic Shock
批准号:
10302289
负责人:
Wen Xie
金额:
$35.21万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-01-15 至 2023-11-30
关键词:
AblationAntioxidantsAttenuatedCYP3A4 geneClinicalClinical ManagementCytochrome P450DataDrug TargetingDrug usageEnsureEnzymesExhibitsGeneticGoalsHemorrhagic ShockHepaticInflammatoryInjuryKnock-outLeadLifeLiverMediatingMetabolismMidazolamMolecularMusN-AcetylcysteinamideOutcomeOxidative StressOxidative Stress InductionOxycodonePathogenesisPatientsPharmaceutical PreparationsPharmacologyPhasePlayProductionReactive Oxygen SpeciesReceptor ActivationRegulationReportingRoleTestingTissuesTranscriptional RegulationTransgenesTransgenic MiceTraumaTrauma patientTraumatic injuryXenobioticsantagonistbaseconstitutive androstane receptordrug metabolismhumanized mouseinjuredliver injurylung injurynew therapeutic targetoxidationpregnane X receptorprimary outcomeresponsetempoltrauma care
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Title: PXR-Mediated Xenobiotic Response in the Pathogenesis Hemorrhagic Shock
Project Summary/Abstract:
The goal of this proposal is to understand the role of xenobiotic receptor pregnane X receptor (PXR) in the
pathogenesis and clinical outcome of hemorrhagic shock (HS). HS is a life-threatening condition often
associated with traumatic injuries. Severe HS can lead to injury to multiple tissues, including the liver. In
addition to the liver injury, HS and the resulting tissue hypofusion also induce a cascade of inflammatory and
oxidative stress, leading to an overall suppression of drug metabolism in the liver. The HS-responsive
suppression of hepatic drug metabolism has potential clinical implications, because seriously injured trauma
patients are uniformly prescribed with multiple medications.
PXR is a master regulator of xenobiotic response through its transcriptional regulation of the phase I and
phase II drug-metabolizing enzymes (DMEs) and transporters, especially in the liver. In addition to inducing
cytochrome P450 (CYP) enzymes, another potential outcome of PXR activation is the increased production of
reactive oxygen species (ROS) as a result of increased CYP-mediated oxidations. Many of the drugs often
prescribed to the HS patients before or after the occurrence of trauma, such as RIF and DEX, are known PXR
activators and DME inducers in the liver. It has also been reported that the expression and activity of PXR
decreased in experimental HS. However, it is unclear whether PXR plays a role in the regulation of
hepatic drug metabolism in the setting of HS and if so, whether activation of PXR is beneficial or
detrimental to the HS-responsive liver injury.
Our preliminary results showed that: 1) Mice subjected to HS exhibit a dynamic regulation of PXR and hepatic
P450 enzymes, such as the Cyp3a11; 2) HS suppresses the metabolism of midazolam and Oxycodone, two
drugs commonly used in trauma care; 3) Genetic activation of PXR in transgenic mice sensitizes mice to HS-
responsive liver injury, but had little effect on HS-responsive lung injury; 4) The HS-responsive liver injury, but
not lung injury, was attenuated in Pxr-/- mice; 5) The sensitizing effect of the PXR transgene on HS-induced
liver injury is Cyp3a dependent; 6) The sensitizing effect of the PXR transgene on HS-responsive liver injury is
associated with increased hepatic oxidative stress; 7) The hPXR-hCYP3A4 humanized mice have been
created; and 8) Activation of constitutive androstane receptor (CAR) does not affect HS-responsive liver injury.
Based on these observations, we propose a reciprocal interaction between hemorrhagic shock (HS) and
hepatic drug metabolism or the regulation of hepatic drug metabolism. Specifically, we hypothesize
that 1) HS causes liver damage and has a dynamic effect on the expression of PXR, CYP3A and other
DMEs; and 2) Activation of PXR sensitizes HS-responsive liver injury by inducing the expression of
CYP3A and increasing oxidative stress. We propose three specific aims to test our hypotheses: 1) To
determine whether pharmacological activation of PXR in humanized mice sensitizes them to HS-induced liver
injury; 2) To determine whether the expression and regulation of CYP3A4 in humanized mice are required for
the sensitizing effect of PXR on HS-induced liver injury; and 3) To determine whether the induction of oxidative
stress is responsible for the sensitizing effect of PXR on HS-induced liver injury in humanized mice.
Taken together, our results suggest that the HS-responsive suppression of PXR may represent a protective
response and/or secondary response to HS-induced liver injury. The unavoidable use of PXR-activating drugs
prior to HS or during the clinical management of trauma may restore drug metabolism, but has the potential to
exacerbate HS-induced liver injury in trauma patients, which can be mitigated by the co-administration of anti-
oxidative agents or PXR antagonists.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
-
批准号:10411925
-
项目类别:
-
资助金额:$86.43万
-
财政年份:2019
-
负责人:Wen Xie
-
依托单位:
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
-
批准号:10194495
-
项目类别:
-
资助金额:$87.56万
-
财政年份:2019
-
负责人:Wen Xie
-
依托单位:
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
-
批准号:10623308
-
项目类别:
-
资助金额:$85.57万
-
财政年份:2019
-
负责人:Wen Xie
-
依托单位:
The hepatic function of cholesterol sulfotransferase 2B1b (SULT2B1b)in energy met
-
批准号:8754531
-
项目类别:
-
资助金额:$33.5万
-
财政年份:2014
-
负责人:Wen Xie
-
依托单位:
The hepatic function of cholesterol sulfotransferase 2B1b (SULT2B1b)in energy met
-
批准号:9087207
-
项目类别:
-
资助金额:$33.5万
-
财政年份:2014
-
负责人:Wen Xie
-
依托单位:
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase
-
批准号:8895932
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2014
-
负责人:Wen Xie
-
依托单位:
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase
-
批准号:9265092
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2014
-
负责人:Wen Xie
-
依托单位:
A Novel Regulation of the Phase II Enzyme Estrogen Sulfotransferase
-
批准号:9060933
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2014
-
负责人:Wen Xie
-
依托单位:
The Perinatal Pharmacology of the Nuclear Receptor
-
批准号:8628853
-
项目类别:
-
资助金额:$30.76万
-
财政年份:2013
-
负责人:Wen Xie
-
依托单位:
The Perinatal Pharmacology of the Nuclear Receptor
-
批准号:9043915
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2013
-
负责人:Wen Xie
-
依托单位:
The Perinatal Pharmacology of the Nuclear Receptor
-
批准号:8477898
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2013
-
负责人:Wen Xie
-
依托单位:
The Regulation of Human Hydroxysteroid Sulfotransferase by Nuclear Receptor ROR
-
批准号:8028983
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2011
-
负责人:Wen Xie
-
依托单位:
The Regulation of Human Hydroxysteroid Sulfotransferase by Nuclear Receptor ROR
-
批准号:8210824
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2011
-
负责人:Wen Xie
-
依托单位:
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis
-
批准号:8248808
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2010
-
负责人:Wen Xie
-
依托单位:
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis
-
批准号:8446377
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2010
-
负责人:Wen Xie
-
依托单位:
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis
-
批准号:8066270
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2010
-
负责人:Wen Xie
-
依托单位:
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis
-
批准号:8639550
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2010
-
负责人:Wen Xie
-
依托单位:
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis
-
批准号:7881176
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2010
-
负责人:Wen Xie
-
依托单位:
The AHR-FGF221 Axis in Hepatic Steatosis and Metobolic Syndrome
-
批准号:9120589
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2010
-
负责人:Wen Xie
-
依托单位:
The AHR-FGF221 Axis in Hepatic Steatosis and Metobolic Syndrome
-
批准号:9249571
-
项目类别:
-
资助金额:$34.9万
-
财政年份:2010
-
负责人:Wen Xie
-
依托单位:
海外基金